Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection

Hiromitsu Kumada, Tsunamasa Watanabe, Fumitaka Suzuki, Kenji Ikeda, Ken Sato, Hidenori Toyoda, Masanori Atsukawa, Akio Ido, Akinobu Takaki, Nobuyuki Enomoto, Koji Kato, Katia Alves, Margaret Burroughs, Rebecca Redman, David Pugatch, Tami J. Pilot-Matias, Preethi Krishnan, Rajneet K. Oberoi, Wangang Xie, Kazuaki Chayama

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Unfortunately, in the original publication of this article, the copyright line was incorrectly published in PDF as “

Original languageEnglish
Number of pages1
JournalJournal of Gastroenterology
DOIs
Publication statusAccepted/In press - Nov 13 2017

    Fingerprint

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Kumada, H., Watanabe, T., Suzuki, F., Ikeda, K., Sato, K., Toyoda, H., Atsukawa, M., Ido, A., Takaki, A., Enomoto, N., Kato, K., Alves, K., Burroughs, M., Redman, R., Pugatch, D., Pilot-Matias, T. J., Krishnan, P., Oberoi, R. K., Xie, W., & Chayama, K. (Accepted/In press). Correction to: Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. Journal of Gastroenterology. https://doi.org/10.1007/s00535-017-1409-z